Azitra, Inc.: Ayrton Capital LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Ayrton Capital LLC amended its Schedule 13G filing on Azitra, Inc., updating its beneficial ownership stake with the SEC under accession number 0001493152-26-051273. The filing reflects a change in the investment firm's position in the clinical-stage dermatology company. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts relative to the 5% threshold. The update signals a shift in Ayrton's holdings that could draw attention from investors tracking institutional interest in the small-cap biotech. What to watch next is whether the amended stake reflects accumulation or reduction, and whether further 13G or 13D filings follow.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Azitra, Inc., Ayrton Capital LLC